4-1BB bispecific antibody - Beijing Immunoah Pharma Tech
Latest Information Update: 29 Jul 2024
At a glance
- Originator Beijing Immunoah Pharma Tech
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Jul 2024 Preclinical trials in Solid tumours in China (Parenteral)